GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mirum Pharmaceuticals Inc (NAS:MIRM) » Definitions » Beneish M-Score

Mirum Pharmaceuticals (Mirum Pharmaceuticals) Beneish M-Score : -2.06 (As of May. 05, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Mirum Pharmaceuticals Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.06 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Mirum Pharmaceuticals's Beneish M-Score or its related term are showing as below:

MIRM' s Beneish M-Score Range Over the Past 10 Years
Min: -2.06   Med: -0.65   Max: 0.77
Current: -2.06

During the past 6 years, the highest Beneish M-Score of Mirum Pharmaceuticals was 0.77. The lowest was -2.06. And the median was -0.65.


Mirum Pharmaceuticals Beneish M-Score Historical Data

The historical data trend for Mirum Pharmaceuticals's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mirum Pharmaceuticals Beneish M-Score Chart

Mirum Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial - - - 0.77 -2.06

Mirum Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.77 -0.85 -2.81 -2.01 -2.06

Competitive Comparison of Mirum Pharmaceuticals's Beneish M-Score

For the Biotechnology subindustry, Mirum Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mirum Pharmaceuticals's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mirum Pharmaceuticals's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Mirum Pharmaceuticals's Beneish M-Score falls into.



Mirum Pharmaceuticals Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Mirum Pharmaceuticals for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1713+0.528 * 1.1228+0.404 * 0.8751+0.892 * 2.4185+0.115 * 0.6866
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.6772+4.679 * -0.062743-0.327 * 3.2596
=-2.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $68.0 Mil.
Revenue was 69.554 + 47.725 + 37.497 + 31.598 = $186.4 Mil.
Gross Profit was 44.534 + 37.497 + 30.685 + 26.619 = $139.3 Mil.
Total Current Assets was $387.5 Mil.
Total Assets was $646.6 Mil.
Property, Plant and Equipment(Net PPE) was $2.0 Mil.
Depreciation, Depletion and Amortization(DDA) was $10.8 Mil.
Selling, General, & Admin. Expense(SGA) was $145.9 Mil.
Total Current Liabilities was $87.1 Mil.
Long-Term Debt & Capital Lease Obligation was $307.0 Mil.
Net Income was -35.659 + -23.588 + -74.038 + -30.13 = $-163.4 Mil.
Non Operating Income was -3.061 + 1.322 + -49.35 + -0.811 = $-51.9 Mil.
Cash Flow from Operations was -16.618 + -18.221 + -2.331 + -33.774 = $-70.9 Mil.
Total Receivables was $24.0 Mil.
Revenue was 27.906 + 18.78 + 17.484 + 12.892 = $77.1 Mil.
Gross Profit was 23.412 + 15.848 + 14.96 + 10.468 = $64.7 Mil.
Total Current Assets was $190.2 Mil.
Total Assets was $352.9 Mil.
Property, Plant and Equipment(Net PPE) was $2.3 Mil.
Depreciation, Depletion and Amortization(DDA) was $3.2 Mil.
Selling, General, & Admin. Expense(SGA) was $89.1 Mil.
Total Current Liabilities was $64.7 Mil.
Long-Term Debt & Capital Lease Obligation was $1.3 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(67.968 / 186.374) / (23.994 / 77.062)
=0.364686 / 0.31136
=1.1713

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(64.688 / 77.062) / (139.335 / 186.374)
=0.839428 / 0.74761
=1.1228

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (387.541 + 1.99) / 646.621) / (1 - (190.225 + 2.345) / 352.906)
=0.39759 / 0.454331
=0.8751

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=186.374 / 77.062
=2.4185

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(3.238 / (3.238 + 2.345)) / (10.829 / (10.829 + 1.99))
=0.579975 / 0.844762
=0.6866

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(145.88 / 186.374) / (89.066 / 77.062)
=0.782727 / 1.155771
=0.6772

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((307.038 + 87.064) / 646.621) / ((1.257 + 64.729) / 352.906)
=0.609479 / 0.186979
=3.2596

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-163.415 - -51.9 - -70.944) / 646.621
=-0.062743

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Mirum Pharmaceuticals has a M-score of -2.06 suggests that the company is unlikely to be a manipulator.


Mirum Pharmaceuticals Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Mirum Pharmaceuticals's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Mirum Pharmaceuticals (Mirum Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
950 Tower Lane, Suite 1050, Foster City, CA, USA, 94404
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Executives
Peter Radovich officer: Chief Operating Officer C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Jolanda Howe officer: SVP, Global Controller C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY CA 94404
Lara Longpre officer: Chief Development Officer C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY CA 94404
Pamela Vig officer: Chief Scientific Officer C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY CA 94404
Christopher Peetz director, officer: President and CEO C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, #200, SOUTH SAN FRANCISCO CA 94080
Patrick J Heron director, 10 percent owner 550 HAMILTON AVE., SUITE 100, PALO ALTO CA 94301
Michael G Grey director, officer: Executive Chairman C/O SGX PHARMACEUTICALS, INC., 10505 ROSELLE STREET, SAN DIEGO CA 92121
Eric Bjerkholt officer: Chief Financial Officer 132 PURDURE AVENUE, KENGSINGTON CA 94708
Timothy P Walbert director 1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062
Lon Cardon director C/O RENEO PHARMACEUTICALS, INC., 12230 EL CAMINO REAL, SUITE 230, SAN DIEGO CA 92130
Niall O'donnell director C/O RIVERVEST VENTURE PARTNERS, 101 SOUTH HANLEY RD., STE 1850, ST. LOUIS MO 63105
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Saira Ramasastry director 501 CANAL BLVD., RICHMOND CA 94804
Ian Clements officer: SVP Finance & Communications C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY CA 94404
Edwin Jonathan Tucker officer: Chief Medical Officer C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY CA 94404